Takeda Pharmaceutical Co (TAK) Stock Price, Quote, News & History

Takeda Pharmaceutical Co Ltd (TAK) Stock Price, Quote, News & History

TAKNYSE

$18.76

-0.01-0.05%

Last update: Apr 2, 2:53 PM

M&A: Takeda Pharmaceutical Co (TAK) announced it will sell assets to Axsome Therapeutics (AXSM) on Wednesday, April 1, 2026

Key Statistics

Open

$18.56

Volume / Avg.

1.89M / 2.98M

Day Range

$18.46 - $18.83

52 Wk Range

12.99 - 18.90

Market Cap

$59.27B

P/E Ratio

84.92

Dividend Yield

3.52%

Exchange

NYSE

RSI

Short Interest

0.19%

Days to Cover

2.29

Recent Takeda Pharmaceutical Co Ltd News

Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.

Vandana Singh

What's Going On With Eli Lilly On Monday?

Global CEOs signal cautious China expansion as Eli Lilly ramps investment, while the Supreme Court revives Actos litigation risks.

Vandana Singh

Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps

Takeda shares are down slightly on Friday morning after positive Phase 3 Entyvio data show strong remission rates in ulcerative colitis trial.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.19T

Investing Cash Flow (TTM)

-330.81B

Financing Cash Flow (TTM)

-721.12B

Free Cash Flow (TTM)

746.07B

Capital Expenditure (TTM)

-442.99B

Net Change in Cash (TTM)

137.14B

Analyst Rating and Forecast

4.7

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$84.44B

PE Ratio (TTM)

84.92

PE Ratio (FWD)

13.04

PEG Ratio (TTM)

0.41

PS Ratio (TTM)

2.15

PB Ratio (TTM)

1.24

Earnings Yield % (TTM)

1.19%

Earnings Yield % (FWD)

7.67%

EV / EBITDA (TTM)

10.77

Price / EBITDA (TTM)

7.73

Price / Free Cash Flow (TTM)

12.89

Book Value / Share

$15.26

Company Debt

Total Debt

$4.85T

LT Debt

$4.27T

LT Debt Issuance (TTM)

$526.06B

LT Debt Repayment (TTM)

-$705.58B

Total Cash

$654.94B

Debt to Equity

0.64

Issuance of Debt (TTM)

-$179.52B

Repayment of Debt (TTM)

-$705.58B

Key Statistics

Open

$18.56

Volume / Avg.

1.89M / 2.98M

Day Range

$18.46 - $18.83

52 Wk Range

12.99 - 18.90

Market Cap

$59.27B

P/E Ratio

84.92

Dividend Yield

3.52%

Exchange

NYSE

RSI

Short Interest

0.19%

Days to Cover

2.29

About

Sector

Health Care

Industry

Pharmaceuticals

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, whi...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

How do I buy Takeda Pharmaceutical Co (TAK) stock?

You can purchase shares of Takeda Pharmaceutical Co (NYSE:TAK) through any online brokerage.

View our list of the best stock brokerages

Who are Takeda Pharmaceutical Co (TAK) competitors?

Other companies in Takeda Pharmaceutical Co’s space includes: Novo Nordisk AS (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and Terns Pharmaceuticals Inc (NASDAQ:TERN).

What is the forecast, or price target, for Takeda Pharmaceutical Co (TAK) stock?

Takeda Pharmaceutical Co has a consensus price target of $20.00.

What is the current price for Takeda Pharmaceutical Co (TAK)?

The stock price for Takeda Pharmaceutical Co (NYSE: TAK) is $18.76 last updated April 2, 2026 at 2:53 PM EDT.

Does Takeda Pharmaceutical Co (TAK) pay a dividend?

There are no upcoming dividends for Takeda Pharmaceutical Co.

When is Takeda Pharmaceutical Co (NYSE:TAK) reporting earnings?

Takeda Pharmaceutical Co does not have any upcoming earnings scheduled.

Is Takeda Pharmaceutical Co (TAK) going to split?

There is no upcoming split for Takeda Pharmaceutical Co.

What sector and industry does Takeda Pharmaceutical Co (TAK) operate in?

Takeda Pharmaceutical Co is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.

People Also Watch

Terns Pharmaceuticals Inc

Axsome Therapeutics Inc

NASDAQ:AXSM

$168.15

-2.12%

Key Statistics

Open

$18.56

Volume / Avg.

1.89M / 2.98M

Day Range

$18.46 - $18.83

52 Wk Range

12.99 - 18.90

Market Cap

$59.27B

P/E Ratio

84.92

Dividend Yield

3.52%

Exchange

NYSE

RSI

Short Interest

0.19%

Days to Cover

2.29

Recent Takeda Pharmaceutical Co Ltd News

Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.

Vandana Singh

What's Going On With Eli Lilly On Monday?

Global CEOs signal cautious China expansion as Eli Lilly ramps investment, while the Supreme Court revives Actos litigation risks.

Vandana Singh

Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps

Takeda shares are down slightly on Friday morning after positive Phase 3 Entyvio data show strong remission rates in ulcerative colitis trial.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.19T

Investing Cash Flow (TTM)

-330.81B

Financing Cash Flow (TTM)

-721.12B

Free Cash Flow (TTM)

746.07B

Capital Expenditure (TTM)

-442.99B

Net Change in Cash (TTM)

137.14B

Analyst Rating and Forecast

4.7

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$84.44B

PE Ratio (TTM)

84.92

PE Ratio (FWD)

13.04

PEG Ratio (TTM)

0.41

PS Ratio (TTM)

2.15

PB Ratio (TTM)

1.24

Earnings Yield % (TTM)

1.19%

Earnings Yield % (FWD)

7.67%

EV / EBITDA (TTM)

10.77

Price / EBITDA (TTM)

7.73

Price / Free Cash Flow (TTM)

12.89

Book Value / Share

$15.26

Company Debt

Total Debt

$4.85T

LT Debt

$4.27T

LT Debt Issuance (TTM)

$526.06B

LT Debt Repayment (TTM)

-$705.58B

Total Cash

$654.94B

Debt to Equity

0.64

Issuance of Debt (TTM)

-$179.52B

Repayment of Debt (TTM)

-$705.58B

Key Statistics

Open

$18.56

Volume / Avg.

1.89M / 2.98M

Day Range

$18.46 - $18.83

52 Wk Range

12.99 - 18.90

Market Cap

$59.27B

P/E Ratio

84.92

Dividend Yield

3.52%

Exchange

NYSE

RSI

Short Interest

0.19%

Days to Cover

2.29

About

Sector

Health Care

Industry

Pharmaceuticals

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry